Review
Version 1
This version is not peer-reviewed
Summary of Drugs for Canine Parvovirus
Version 1
: Received: 20 August 2024 / Approved: 20 August 2024 / Online: 21 August 2024 (04:34:13 CEST)
How to cite: Fu, J.; Shan, Z.; Qu, H. Summary of Drugs for Canine Parvovirus. Preprints 2024, 2024081506. https://doi.org/10.20944/preprints202408.1506.v1 Fu, J.; Shan, Z.; Qu, H. Summary of Drugs for Canine Parvovirus. Preprints 2024, 2024081506. https://doi.org/10.20944/preprints202408.1506.v1
Abstract
Canine parvovirus (CPV) infection is a widespread ailment among young dogs globally, characterized by high morbidity, mortality, and significant infectivity. Due to its grim prognosis, it is often likened to canine "cancer" with a medium-term mortality rate of 46.43% and late-stage mortality reaching up to 100%.Current treatment modalities primarily encompass fluid therapy, antiemetics, antimicrobial medications, pain relievers, and enteral nutrition. However, the absence of specific internationally recognized medications necessitates substantial care expenses. This review aims to elucidate recent advancements in pharmacological interventions for mitigating CPV infection symptoms, underscoring the potential of novel pharmaceutical technologies in veterinary medicine to enhance clinical outcomes for afflicted animals and their caregivers，lay a theoretical foundation for the development of specific drugs.
Keywords
canine parvovirus infection; drug therapy; veterinary medicine
Subject
Medicine and Pharmacology, Veterinary Medicine
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
